Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1430 participants.
Also called NCT04797013
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,430 participants
- Registry
-
NCT04797013
-
- Other papers using this trial's data
- Efficacy and Safety of Intravenous Tenecteplase Versus Alteplase in Treating Acute Ischemic Stroke With Diabetes and Admission Hyperglycemia
- Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04797013. Randomized; single masking; primary purpose treatment. Start 2021-06-12 (actual); primary completion 2022-05-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ
- Acronym
- TRACEⅡ
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- rt-PA
- Intervention (Drug)
- rhTNK-tPA
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Record details
- Record id
cardio:ct-nct04797013- Content hash
450617e88e49544a6245f8ed3b1ba78be7dc0537d6c4fe6dc9d9d108a31f9fe9